- Home
- AFRI vs RXST Comparison
AFRI vs RXST Comparison
Compare AFRI & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRI | RXST |
|---|---|---|
| Founded | 1943 | 1997 |
| Country | Gibraltar | United States |
| Employees | 600 | N/A |
| Industry | Packaged Foods | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.2M | 300.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AFRI | RXST |
|---|---|---|
| Price | $10.00 | $6.06 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.78 |
| AVG Volume (30 Days) | 19.3K | ★ 633.7K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.47 | $5.30 |
| 52 Week High | $11.42 | $16.47 |
Technical Indicators
Market Signals| Indicator | AFRI | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 43.33 |
| Support Level | $9.87 | $5.90 |
| Resistance Level | $10.00 | $7.60 |
| Average True Range (ATR) | 0.20 | 0.37 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 28.32 | 38.27 |
Price Performance
Historical ComparisonAbout AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.